Compare ARVN & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | GAU |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 606.0M |
| IPO Year | 2018 | 2006 |
| Metric | ARVN | GAU |
|---|---|---|
| Price | $8.04 | $1.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 2 |
| Target Price | ★ $15.05 | $4.08 |
| AVG Volume (30 Days) | 680.3K | ★ 3.7M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | N/A | $82.77 |
| Revenue Next Year | N/A | $29.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $1.22 |
| 52 Week High | $14.22 | $3.62 |
| Indicator | ARVN | GAU |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 36.46 |
| Support Level | $7.35 | N/A |
| Resistance Level | $10.18 | $2.75 |
| Average True Range (ATR) | 0.41 | 0.12 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 70.20 | 18.55 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.